154 related articles for article (PubMed ID: 31809308)
21. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
[TBL] [Abstract][Full Text] [Related]
22. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
[TBL] [Abstract][Full Text] [Related]
23. Qualitative Perceptions of Dapivirine VR Adherence and Drug Level Feedback Following an Open-Label Extension Trial.
Naidoo K; Mansoor LE; Katz AWK; Garcia M; Kemigisha D; Morar NS; Zimba CC; Chitukuta M; Reddy K; Soto-Torres L; Naidoo S; Montgomery ET
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):e90-e96. PubMed ID: 33278181
[TBL] [Abstract][Full Text] [Related]
24. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
[TBL] [Abstract][Full Text] [Related]
25. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
[TBL] [Abstract][Full Text] [Related]
26. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
27. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
[TBL] [Abstract][Full Text] [Related]
28. First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.
van der Straten A; Browne EN; Shapley-Quinn MK; Brown ER; Reddy K; Scheckter R; Soto-Torres L; Palanee-Phillips T; Baeten JM; Mensch B;
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):304-310. PubMed ID: 30844995
[TBL] [Abstract][Full Text] [Related]
29. Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring.
Balkus JE; Brown ER; Palanee-Phillips T; Matovu Kiweewa F; Mgodi N; Naidoo L; Mbilizi Y; Jeenarain N; Gaffoor Z; Siva S; Nair G; Pather A; Baeten JM
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):e8-e10. PubMed ID: 28961677
[No Abstract] [Full Text] [Related]
30. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
[TBL] [Abstract][Full Text] [Related]
31. Receptive anal sex contributes substantially to heterosexually acquired HIV infections among at-risk women in twenty US cities: Results from a modelling analysis.
Elmes J; Silhol R; Hess KL; Gedge LM; Nordsletten A; Staunton R; Anton P; Shacklett B; McGowan I; Dang Q; Adimora AA; Dimitrov DT; Aral S; Handanagic S; Paz-Bailey G; Boily MC
Am J Reprod Immunol; 2020 Aug; 84(2):e13263. PubMed ID: 32384198
[TBL] [Abstract][Full Text] [Related]
32. Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies.
McGowan I; Taylor DJ
Sex Transm Dis; 2010 Jun; 37(6):361-4. PubMed ID: 20514687
[TBL] [Abstract][Full Text] [Related]
33. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.
Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL
J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936
[TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
[TBL] [Abstract][Full Text] [Related]
35. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
Bunge KE; Dezzutti CS; Rohan LC; Hendrix CW; Marzinke MA; Richardson-Harman N; Moncla BJ; Devlin B; Meyn LA; Spiegel HM; Hillier SL
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):498-505. PubMed ID: 26565716
[TBL] [Abstract][Full Text] [Related]
36. Development of dapivirine vaginal ring for HIV prevention.
Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
38. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
[TBL] [Abstract][Full Text] [Related]
39. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
[TBL] [Abstract][Full Text] [Related]
40. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]